In a recent transaction, Robert Andrew Berman, the Chief Executive Officer of enVVeno Medical (TASE:) Corp (NASDAQ:NVNO), purchased 12,000 shares of the company’s common stock. The shares were acquired at a weighted average price of approximately $2.55, with the total transaction valued at $30,599. The purchase comes as the stock trades near its 52-week low of $2.50, with technical indicators suggesting oversold conditions according to InvestingPro analysis. Following this acquisition, Berman’s direct ownership in the company increased to 222,236 shares. This purchase reflects Berman’s continued investment in the Irvine, California-based medical device company, which maintains a strong balance sheet with more cash than debt and an impressive current ratio of 22.01. The company’s current market capitalization stands at $44.54 million, and InvestingPro analysis suggests the stock is slightly undervalued at current levels. [Discover 10+ additional exclusive insights and real-time metrics with InvestingPro]
In other recent news, enVVeno Medical Corporation has made significant strides in the medical device field. The company has recently submitted its Premarket Approval (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA). The VenoValve, a device designed to treat Chronic Venous Insufficiency (CVI), has received approval for four out of five modules of the PMA application. The final module, which includes clinical data from the SAVVE pivotal trial, is currently under review.
In addition to the VenoValve, enVVeno Medical is also developing a non-surgical transcatheter-based replacement venous valve, enVVe, expected to enter a pivotal trial by mid-2025. The company has also launched a public stock offering, managed by Titan Partners Group, to support the development of these leading products. Recent executive appointments, including Sandy Prietto as Vice President of Marketing and Andrew Cormack as Chief Commercial Officer, indicate a strategic shift towards commercialization.
The company’s financial position remains robust, with $39.1 million in cash and investments reported at the end of a recent quarter. These funds are expected to sustain operations through the end of 2025. These are the latest developments in enVVeno Medical Corporation’s ongoing efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
